Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...4142434445464748495051...7475»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Pharmacotherapy of Myopic Choroidal Neovascularization. (Pubmed Central) -  Nov 23, 2019   
    The results of this study can serve as a reference for clinicians to provide patient-tailored treatment. Anti-VEGF therapy is generally very effective in the treatment of myopic CNV.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Pharmacotherapy for choroidal neovascularization due to uncommon causes. (Pubmed Central) -  Nov 23, 2019   
    Anti-VEGF therapy is generally very effective in the treatment of myopic CNV. Pharmacotherapy with anti-VEGF agents is an effective treatment option for CNV due to uncommon etiologies.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  The Impact of Prefilled Syringes on Endophthalmitis following Intravitreal Injection of Ranibizumab. (Pubmed Central) -  Nov 21, 2019   
    Lower BCVA, younger age and presence of subretinal fluid were predictive of early vision improvement. In a large, multicenter, retrospective study the use of prefilled syringes during intravitreal injection of ranibizumab was associated with a reduced rate of culture-positive endophthalmitis, including from oral flora, as well as with improved visual acuity outcomes.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment change, Trial termination:  DORO: Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab (clinicaltrials.gov) -  Nov 20, 2019   
    P4,  N=4, Terminated, 
    In a large, multicenter, retrospective study the use of prefilled syringes during intravitreal injection of ranibizumab was associated with a reduced rate of culture-positive endophthalmitis, including from oral flora, as well as with improved visual acuity outcomes. N=120 --> 4 | Recruiting --> Terminated; Enrollment pace was far below target.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. (Pubmed Central) -  Nov 20, 2019   
    A total of 65 (10.4%) and 83 (13.3%) eyes reached and sustained (≥2 consecutive injection intervals of the same length) an 8 and 12 weekly interval, respectively. This study demonstrates highly individualised treatment patterns in the first year of anti-VEGF therapy in Australia using T&E regimens, with the majority of patients requiring more frequent injections than once every 8 weeks.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Role of TLR4-MAP4K4 signaling pathway in models of oxygen-induced retinopathy. (Pubmed Central) -  Nov 14, 2019   
    The effects were further potentiated by the anti-VEGF antibody ranibizumab...Down-regulation of MAP4K4 in HRMECs abolished the proangiogenic effects by LPS. Our data suggest that the TLR4-MAP4K4 pathway can regulate retinal neovascularization via mechanisms independent of VEGF.-Chen, W., Zhang, J., Zhang, P., Hu, F., Jiang, T., Gu, J., Chang, Q. Role of TLR4-MAP4K4 signaling pathway in models of oxygen-induced retinopathy.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  The association of choroidal structure and its response to anti-VEGF treatment with the short-time outcome in pachychoroid neovasculopathy. (Pubmed Central) -  Nov 10, 2019   
    In non-PNV, change of luminal area (coefficient = 7.0×10-5, p = 0.0001), baseline CNV area (coefficient = 0.18, p = 0.033), and aflibercept vs. ranibizumab (coefficient = 0.29, p = 0.0048) were chosen as predictors for dry macula by the model selection...In PNV, however, none of these factors was chosen as predictors for dry macula or VA improvement by the model selection. The result of the present study implied that structural response after anti-VEGF might be different between non-PNV and PNV in the treatment with anti-VEGF agents.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity. (Pubmed Central) -  Nov 7, 2019   
    Although initial studies on anti-VEGF therapy for ROP have focused on bevacizumab, recent studies have proposed that ranibizumab may be a safer and more effective alternative for use in this population. This review updates recent evidence regarding the use of ranibizumab in the management of ROP.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    PK/PD data, Journal:  Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules. (Pubmed Central) -  Nov 7, 2019   
    Impacts of charge and hydrophobicity on vitreal PK in the rabbit were systematically assessed using antibody and antibody fragment (Fab) variant series, including ranibizumab, altered through amino acid changes in hypervariable regions of the light chain...Diffusive properties of soluble large molecules, as quantified by hydrodynamic radius, make a key contribution to vitreal elimination, whereas differences in charge or hydrophobicity make minor or negligible contributions. These results support estimation of vitreal elimination rates based on molecular size in relevant preclinical species and humans.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice. (Pubmed Central) -  Oct 31, 2019   
    Standard treatment strategies are based on anti-VEGF administration, including standard loading dose administration followed by maintenance with aflibercept or ranibizumab (81% of patients)...However, their proper implementation is difficult due to healthcare resource limitations, as well as organisation and logistic issues. The use of anti-VEGF agents with longer duration of action could facilitate the use of strict T&E approaches according to routine clinical practices.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
    Trial initiation date, Monotherapy:  Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) -  Oct 28, 2019   
    P4,  N=150, Not yet recruiting, 
    This model could therefore be a useful tool to predict the outcomes of different, more patient-tailored treatment regimens in nAMD. Initiation date: Oct 2019 --> Jan 2020
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy. (Pubmed Central) -  Oct 27, 2019   
    Targeted knockdown of VEGFR2 or STAT3 specifically in retinal endothelial cells by subretinal injection of lentiviral vectors into postnatal day 8 rat pup eyes efficiently inhibited IVNV, and knockdown of VEGFR2 also reduced AVA and increased retinal thickness without altering retinal function. Taken together, our results support specific knockdown of VEGFR2 in retinal endothelial cells as a novel therapeutic method to treat retinopathy.
  • ||||||||||  nesvacumab (REGN910) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. (Pubmed Central) -  Oct 27, 2019   
    AKB-9778 is a subcutaneously administered VE-PTP inhibitor that, when combined with monthly ranibizumab, reduced DME more effectively than ranibizumab monotherapy in a phase 2 study...AXT107, currently in the preclinical phase, promotes conversion of Ang-2 into a Tie-2 agonist and blocks signaling through VEGFR2 and other receptor tyrosine-kinases. Expert Opinion: Tie-2/Angiopoietin pathway modulators show promise to reduce treatment burden and improve visual outcomes in nAMD and DME, with potential to treat cases refractory to current treatment modalities.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Extensive Submacular Hemorrhage after Trabeculectomy with Mitomycin C. (Pubmed Central) -  Oct 24, 2019   
    Expert Opinion: Tie-2/Angiopoietin pathway modulators show promise to reduce treatment burden and improve visual outcomes in nAMD and DME, with potential to treat cases refractory to current treatment modalities. To our knowledge, this is the first report of an extensive submacular hemorrhage after trabeculectomy with mitomycin C in a patient with an occult CNVM.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal, Real-World Evidence:  Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan. (Pubmed Central) -  Oct 24, 2019   
    The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Preclinical, Journal:  Inhibitory effects on retinal neovascularization by ranibizumab and sTie2-Fc in an oxygen-induced retinopathy mouse model. (Pubmed Central) -  Oct 24, 2019   
    In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome. In this study, it was confirmed that blocking the Ang/Tie2 and/or VEGF/VEGFR pathways could inhibit RNV and decrease abnormal micro-vessel density; and the mono-blockage of Ang/Tie2 might cause a smaller non-perfusion area.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Renal Damage Associated with Intravitreal Administration of Anti-VEGF Drugs () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5221;    
    58.5% received bevazicumab, while the remaining 41.5% received ranibizumab...On the other hand, within the CKD group, one patient presented two episodes of decompensation of heart failure after administration of an anti-VEGF drug, and two required the initiation of renal replacement therapy. Conclusion Based on the results of our cohort, we believe that it would be advisable to establish a closer monitoring in diabetic patients who are administered an intravitreal anti-VEGF drug, with determination of renal function as well as proteinuria to establish an early diagnosis of possible complications.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Anatomical and functional changes after dexamethasone implant and ranibizumab in diabetic macular edema: a retrospective cohort study. (Pubmed Central) -  Oct 23, 2019   
    Conclusion Based on the results of our cohort, we believe that it would be advisable to establish a closer monitoring in diabetic patients who are administered an intravitreal anti-VEGF drug, with determination of renal function as well as proteinuria to establish an early diagnosis of possible complications. Both treatments are very effective for DME treatment during 6mo of follow-up with a lower retreatment rate in DEX group.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. (Pubmed Central) -  Oct 20, 2019   
    The DRCR Network treatment algorithm for PDR can provide excellent clinical outcomes through two years for patients initiating anti-VEGF therapy for PDR. When choosing between anti-VEGF and PRP as first-line therapy for PDR, treatment decisions should be guided by consideration of the relative advantages of each therapeutic modality and anticipated patient compliance with follow-up and treatment recommendations.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Reimbursement, Journal:  Public Reimbursement of Prescription Drugs Used For Off-Label Indications in Ontario. (Pubmed Central) -  Oct 19, 2019   
    Presently, OPDP only reimburse drugs for off-label use for the treatment of serious, life-threatening or severely debilitating conditions for which no alternative treatment exists. OPDP should not diverge from this approach by allowing cost-savings to trump appropriate drug use, which would set a unique and unprecedented example.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Bilateral proliferative retinopathy and ischemic optic neuropathy in a patient with atypical hemolytic-uremic syndrome: A case report. (Pubmed Central) -  Oct 15, 2019   
    These ischemic retinal changes can then cause hypoxia, which triggers production of angiogenic factors and subsequently causes retinal vascular hyperpermeability, retinal and vitreous neovascularization, fibrovascular proliferation, vitreous hemorrhage, and TRD, in a manner similar to that of other ischemia-induced proliferative retinopathies. Despite successful surgery in the right eye, our patient's visual acuity did not improve, possibly because of severe and generalized ischemia of intraocular tissue, which resulted in ischemic optic neuropathy.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment closed:  CyPov: Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) -  Oct 10, 2019   
    P4,  N=28, Active, not recruiting, 
    With the disappearance of the activity of idiopathic CNV ranibizumab gives real hope to improve visual acuity. Recruiting --> Active, not recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Decision Making in Proliferative Diabetic Retinopathy Treatment. (Pubmed Central) -  Oct 9, 2019   
    Management of PDR requires the identification of high risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.